XTX Topco Ltd Has $667,000 Holdings in CareDx, Inc (NASDAQ:CDNA)

XTX Topco Ltd lifted its holdings in CareDx, Inc (NASDAQ:CDNA - Free Report) by 95.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 31,133 shares of the company's stock after purchasing an additional 15,214 shares during the period. XTX Topco Ltd owned 0.06% of CareDx worth $667,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Thompson Davis & CO. Inc. raised its position in shares of CareDx by 6.3% during the fourth quarter. Thompson Davis & CO. Inc. now owns 16,050 shares of the company's stock valued at $344,000 after buying an additional 950 shares during the last quarter. Legal & General Group Plc raised its position in shares of CareDx by 1.3% during the fourth quarter. Legal & General Group Plc now owns 89,751 shares of the company's stock valued at $1,922,000 after buying an additional 1,118 shares during the last quarter. Sterling Capital Management LLC raised its position in shares of CareDx by 771.2% during the fourth quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock valued at $27,000 after buying an additional 1,126 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of CareDx by 6.5% during the fourth quarter. Principal Financial Group Inc. now owns 18,984 shares of the company's stock valued at $406,000 after buying an additional 1,151 shares during the last quarter. Finally, Plato Investment Management Ltd raised its position in shares of CareDx by 34.1% during the fourth quarter. Plato Investment Management Ltd now owns 5,390 shares of the company's stock valued at $116,000 after buying an additional 1,370 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. StockNews.com raised shares of CareDx from a "hold" rating to a "buy" rating in a research report on Wednesday, February 26th. Wells Fargo & Company raised shares of CareDx from an "underweight" rating to an "equal weight" rating and lowered their target price for the company from $28.00 to $24.00 in a research note on Wednesday, January 15th. The Goldman Sachs Group lowered their target price on shares of CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a research note on Thursday, April 17th. HC Wainwright lowered their target price on shares of CareDx from $26.00 to $25.00 and set a "neutral" rating on the stock in a research note on Monday, March 3rd. Finally, Stephens reissued an "overweight" rating and issued a $40.00 target price on shares of CareDx in a research note on Thursday, February 27th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, CareDx has an average rating of "Moderate Buy" and a consensus price target of $30.33.

CareDx Stock Up 2.0 %

CDNA traded up $0.37 during trading on Thursday, hitting $18.21. The company's stock had a trading volume of 91,437 shares, compared to its average volume of 849,811. The firm's 50 day moving average price is $19.31 and its two-hundred day moving average price is $22.10. CareDx, Inc has a 12 month low of $7.42 and a 12 month high of $34.84. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of -6.74 and a beta of 2.18.

CareDx (NASDAQ:CDNA - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share for the quarter, topping analysts' consensus estimates of $0.05 by $1.46. The company had revenue of $86.58 million during the quarter, compared to the consensus estimate of $84.56 million. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. On average, sell-side analysts forecast that CareDx, Inc will post -0.9 earnings per share for the current year.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.